However, if the tested cell lines accurately model the relevant tumor tissues, the lower sensitivity of RAD51 paralog mutants to PARP inhibitors may predict a reduced clinical response in tumors with the corresponding gene defects. This evidence concerns the gene RAD51 and neoplasm.